HCC
PFE icon

Hirtle Callaghan & Co’s Pfizer PFE Stock Holding History

Hirtle Callaghan & Co’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-36,679
Closed -$1.52M – 116
2018
Q4 		$1.52M Hold
36,679
– – 0.13% 30
2018
Q3 		$1.53M Hold
36,679
– – 0.14% 30
2018
Q2 		$1.26M Hold
36,679
– – 0.12% 33
2018
Q1 		$1.24M Hold
36,679
– – 0.11% 31
2017
Q4 		$1.26M Sell
36,679
-2,007
-5% -$68.4K 0.12% 31
2017
Q3 		$1.31M Buy
38,686
+36,679
+1,828% +$1.18M 0.13% 26
2017
Q2 		$64K Sell
2,007
-499
-20% -$15.7K 0.01% 51
2017
Q1 		$82K Hold
2,506
– – 0.01% 47
2016
Q4 		$78K Sell
2,506
-56,599
-96% -$1.73M 0.01% 50
2016
Q3 		$1.9M Buy
59,105
+17,541
+42% +$587K 0.39% 20
2016
Q2 		$1.39M Sell
41,564
-825
-2% -$26.3K 0.26% 23
2016
Q1 		$1.19M Buy
42,389
+35,435
+510% +$1.01M 0.22% 23
2015
Q4 		$211K Sell
6,954
-11,183
-62% -$352K 0.05% 52
2015
Q3 		$540K Hold
18,137
– – 0.09% 18
2015
Q2 		$577K Buy
+18,137
New +$591K 0.19% 17
2015
Q1 		– Sell
-86,548
Closed -$2.56M – 274
2014
Q4 		$2.56M Buy
86,548
+268
+0.3% +$7.68K 0.59% 33
2014
Q3 		$2.42M Buy
86,280
+17
+0% +$477 0.4% 41
2014
Q2 		$2.43M Sell
86,263
-17
-0% -$485 0.34% 45
2014
Q1 		$2.63M Buy
86,280
+137
+0.2% +$4.08K 0.43% 36
2013
Q4 		$2.5M Buy
86,143
+997
+1% +$29K 0.34% 40
2013
Q3 		$2.32M Buy
85,146
+71,796
+538% +$1.95M 0.37% 45
2013
Q2 		$355K Buy
+13,350
New +$369K 4.11% 8

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Hirtle Callaghan & Co's PFE Position: Q1 2019 in Review

Hirtle Callaghan & Co sold out of Pfizer (PFE) in Q1 2019, closing a stake of 36,679 shares — an estimated $1.52M sold.

Hirtle Callaghan & Co first reported a position in PFE in Q2 2013 and held it in 22 quarters. The position peaked at $2.63M in Q1 2014. 2,391 funds tracked by Wall St. Rank hold PFE as of Q1 2019.

  • Hirtle Callaghan & Co reported no remaining Pfizer position as of Q1 2019 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 36,679 Pfizer shares in Q1 2019, an estimated $1.52M.
  • Hirtle Callaghan & Co first reported a position in Pfizer in Q2 2013 and held it in 22 quarters.
  • Hirtle Callaghan & Co's Pfizer position peaked at $2.63M in Q1 2014.
  • 2,391 funds tracked by Wall St. Rank held Pfizer as of Q1 2019.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2019, filed 14 May 2019.